注册 | 登录 | 充值

首页-> 学术资讯 -> 临床研究

NESTOR研究:长效吲达帕胺和依那普利对降低伴有2型糖尿病高血压患者的微量蛋白尿的作用相同

临床研究

1970-01-01      

1789 0

 Hopital Bichat, Service de Diabetologie et d"Endocrinologie, Paris, France. michel.marre@bch.ap-hop-paris.fr

OBJECTIVES: To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two antihypertensive drugs with opposite effects on the renin-angiotensin system [the diuretic, indapamide sustained release (SR), and an angiotensin-converting enzyme inhibitor, enalapril] in reducing microalbuminuria.

DESIGN: A multinational, multicentre, controlled, double-blind, double-dummy, randomized, two-parallel-groups study over 1 year.

METHODS: After a 4-week placebo run-in period, 570 patients (ages 60.0 +/- 9.9 years, 64% men) with type 2 diabetes, essential hypertension [systolic blood pressure (SBP) 140-180 mmHg, and diastolic blood pressure (DBP) < 110 mmHg], and persistent microalbuminuria (20-200 microg/min) were allocated randomly to groups to receive indapamide SR 1.5 mg (n = 284) or enalapril 10 mg (n = 286) once a day. Amlodipine, atenolol, or both were added, if necessary, to achieve the target blood pressure of 140/85 mmHg.

RESULTS: There was a significant reduction in the urinary albumin : creatinine ratio. Mean reductions were 35% [95% confidence interval (CI) 24 to 43] and 39% (95% CI 30 to 47%) in the indapamide SR and enalapril groups, respectively. Equivalence was demonstrated between the two groups [1.08 (95% CI 0.89 to 1.31%); P = 0.01]. The reductions in mean arterial pressure (MAP) were 16.6 +/- 9.0 mmHg for the indapamide SR group and 15.0 +/- 9.1 mmHg for the enalapril group (NS); the reduction in SBP was significantly greater (P = 0.0245 ) with indapamide SR. More than 50% of patients in each group required additional antihypertensive therapy, with no differences between groups. Both treatments were well tolerated.

CONCLUSIONS: Indapamide-SR-based therapy is equivalent to enalapril-based therapy in reducing microalbuminuria with effective blood pressure reduction in patients with hypertension and type 2 diabetes



科研资讯(站内): NESTOR研究

百度浏览   来源 : 国际循环   


版权声明:本网站所有注明来源“医微客”的文字、图片和音视频资料,版权均属于医微客所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源:”医微客”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,转载仅作观点分享,版权归原作者所有。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。 本站拥有对此声明的最终解释权。

科研搜索(百度):医学科研 NESTOR研究





发表评论

注册或登后即可发表评论

登录注册

全部评论(0)

没有更多评论了哦~

科研资讯 更多>>
  • 肿瘤电场治疗Optune Lua获批治疗..
  • 成本更低的实体瘤抗癌新星:CAR-..
  • 文献速递-子宫内膜癌中的卵黄囊..
  • Nature|MSCs首次用于人体跟腱病..
  • 推荐阅读 更多>>
  • NESTOR研究:长效吲达帕胺对微蛋..
  • PROactive研究:前瞻性吡格列酮..
  • Addition of Clopidogrel to Asp..
  • Val
    • 相关阅读
    • 热门专题
    • 推荐期刊
    • 学院课程
    • 医药卫生
      期刊级别:国家级期刊
      发行周期:暂无数据
      出版地区:其他
      影响因子:暂无数据
    • 中华肿瘤
      期刊级别:北大核心期刊
      发行周期:月刊
      出版地区:北京
      影响因子:1.90
    • 中华医学
      期刊级别:CSCD核心期刊
      发行周期:周刊
      出版地区:北京
      影响因子:0.94